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The determinants of immune recognition by five monoclonal antibodies (KK5, KK9, KK17, Senv7.1, and
SenvlO1.1) that neutralize simian immunodeficiency virus infectivity were analyzed. These five neutralizing
monoclonal antibodies were generated to native SlVmac251 envelope glycoprotein expressed by a vaccinia virus
recombinant vector. All five recognize conformational or discontinuous epitopes and require native antigen for
optimal recognition. These monoclonal antibodies also recognize SlVmac239 gpl20, but they do not recognize
gpl20 of two natural variants of SlVmac239, 1-12 and 8-22, which evolved during the course of persistent
infection in vivo (D. P. W. Burns and R. C. Desrosiers, J. Virol. 65:1843-1854, 1991). Recombinant viruses
which were constructed by exchanging variable regions between SIVmac239 and variant 1-12 were used to
define domains important for recognition. Radioimmunoprecipitation analysis demonstrated that sequence
changes in variable regions 4 and 5 (V4NV5) were primarily responsible for the loss of recognition of the 1-12
variant. Site-specific mutants were used to define precise changes that eliminate recognition by these
neutralizing antibodies. Changing N-409 to D, deletion of KPKE, and deletion of KEQH in V4 each resulted
in loss of recognition by all five monoclonal antibodies. SIVs with these natural sequence changes are still
replication competent and viable. Changing A-417 to T or AIN-417/418 to TK in V4 or Q-477 to K in V5 did not
alter recognition detectably. These results define specific, naturally occurring sequence changes in V4 of
SIVmac that result in loss of recognition by one class of SlVmac neutralizing antibodies.
the appearance of neutralization-resistant HIV-1 variants in
infected humans have been largely hampered by lack of
information on the genetic sequence of the initial infecting
strain and by the presence of an already complex mix of
genotypes in infected humans at the time that samples have
been available for study. Nonetheless, several studies have
indicated that neutralization-resistant HIV-1 variants emerge
during the course of infection (1, 10, 38).
Clear evidence for the emergence of neutralization escape
variants has been presented for rhesus monkeys experimentally
infected with molecularly cloned simian immunodeficiency virus
(SIV) (4). Sequential sera from infected animals showed much
higher neutralizing antibody titers to the cloned virus used for
infection than to cloned variants obtained 69 and 93 weeks after
infection. As an important internal control for the demonstration of immune selection, rhesus monkeys were experimentally
infected with cloned variant virus, and reciprocal neutralization tests were performed with variant-specific sera from these
experimentally infected monkeys. Each cloned virus was neutralized best by its homologous antiserum. Only 20 amino acid
changes in gpl20, mostly in discrete variable domains, were
responsible for the resistance to cross-neutralization.
We now report that natural sequence variation in variable
region 4 (V4) results in loss of recognition by at least one class
of conformation-dependent antibodies that neutralize SIVmac
infectivity.

Antigenic variation during persistent infection has been
extensively studied in three lentiviral systems: visna virus,
caprine arthritis encephalitis virus, and equine infectious anemia virus (7, 12, 21-23, 25, 26, 31). Animals persistently
infected with these ungulate lentiviruses exhibit delayed neutralizing antibody responses against variant viruses which
appear during the course of infection. Results derived from
these lentiviral systems suggest that the host neutralizing
antibody response selects neutralization escape mutants during
the course of viral infection and that antigenic variation may
contribute to persistent viral replication in chronically infected
animals. Sequence changes responsible for resistance of these
ungulate lentiviral variants to serum neutralization have not
been defined. Furthermore, it is difficult to extrapolate the
significance of these findings in ungulate systems to primate
lentiviral systems because of the large phylogenetic distance.
Antibodies that neutralize human immunodeficiency virus
type 1 (HIV-1) in infected people are largely directed against
the envelope glycoprotein gpl20, and a number of linear and
conformationally determined neutralization epitopes have
been identified in this HIV-1-encoded product (for reviews,
see references 28 and 35). However, the relative importance of
different target epitopes in HIV-1-infected people has not
been clearly defined (27, 28, 35, 36). Attempts to demonstrate
*
Corresponding author. Mailing address: New England Regional
Primate Research Center, Harvard Medical School, One Pine Hill Dr.,
Box 9102, Southborough, MA 01772-9102. Phone: (508) 624-8042.
Fax: (508) 624-8190.
t Present address: McArdle Laboratory for Cancer Research, Medical School, University of Wisconsin, Madison, WI 53706.

MATERIALS AND METHODS
Cells and recombinant viruses. Human CD4+ CEMx174
cells were grown in RPMI 1640 medium with 10% fetal calf
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FIG. 1. Amino acid sequence comparisons of gpl20s of SIVmac251, SIVmac239 (33), SIVmacl42 (6), variant 1-12 (5), and variant 8-22 (5).
The sequence of SIVmac251 was derived from the New England Regional Primate Research Center infectious molecular clone (30); its sequence
has not been previously published. Dots represent amino acid identity; dashes represent deletions. Variable regions Vl through V5 are boxed.
Brackets labeled cysteine loop correspond to the V3 cysteine loop which is variable in HIV-1.

serum. Cloned viruses SIVmacl42, SIVmac251, and SIVmac239 and env variants T69 BL1-12 (variant 1-12) and T93
V8-22 (variant 8-22) have been described previously (5, 6, 19,
30, 33). p239SpSp5', p239SpE3', and pl-12SpE3' are plasmid

subclones used to construct recombinant viruses with partially
substituted env sequences (4, 33). Four restriction enzyme sites
corresponding to nucleotides 6822 (HindlIl), 7045 (SpeI), 7758
(MroI), and 8072 (ClaI) were used for the constructions. The
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TABLE 1. Summary of the properties of SIVmac envelope MAbsa
MAb

Binding to env
fragments from
E. Colib

Senv7.1
SenvlOl.1
KK5
KK9
KK17

-

Wester

. .

blot
to Isotype
Bpnedpig
p tiereactivity

-

G1
Gl
G2a
G1
G2a

-

TABLE 2. Relatedness of SIVmac clones

Neutralizing
activity'
atvt

Virus

SIVmac
251

+
+
+
+
+

a Derived from the data of Kent et al. (17, 18) and Collignon et al. (8). + or
- indicates the presence or absence of significant reactivity.
b Fragments corresponding to amino acids 8 to 303, 304 to 492, and 493 to 735
were tested.
c Confirmed by a number of laboratories using a variety of different assays
(11).

numbering system is that of Regier and Desrosiers (33). Vl is
flanked by the HindIII and SpeI sites, and V4 and V5 are
flanked by the MroI and ClaI sites (Fig. 1).
MAbs. The monoclonal antibodies (MAbs) Senv7.1, Senv
101.1, KK5, KK9, and KK17 used for these experiments were
described previously (8, 17, 18). Briefly, these MAbs were
generated by using recombinant vaccinia virus expressing
SIVmac251 gpl60 native antigen for immunization. BALB/c
mice were inoculated intraperitoneally (17) or in the footpads
(8). Four weeks later, these mice were boosted intravenously
(8) or intraperitoneally (17). Mice were sacrificed, and the
spleen cells were fused with the BALB/c myeloma cell line
NSO. Hybridomas were screened by enzyme-linked immunosorbent assay and were cloned in soft agar before being
inoculated into pristine-primed mice for production of ascitic
fluid. The published properties of these MAbs are summarized
in Table 1.
Site-specific mutagenesis. All of the mutations except 415/
416NT->SL and 409D-bN 422-425KEQH were made by using
the single-strand phagemid method according to the instructions of Stratagene (La Jolla, Calif.). (In mutation designations, numbers indicate the positions of the amino acids,
and arrows point to the resultant amino acids.) All of the
primers used for mutagenesis were prepared on a DNA
synthesizer (model 8400; Milligen/Biosearch Inc., Burlington,
Mass.). For the mutagenesis, the HindIII-HincII DNA fragment (nucleotides 6822 to 8244) of p239SpE3' was subcloned
into pBS(-) vector. M13K07 helper phage was used to prepare the single-stranded DNA template. Mutagenic oligonucleotides used for site-specific mutagenesis were as follows: for
the change of codon N-409 (here designated 409N) to D
in V4, W10 (ATGAATTGG'lTTCTAGATTGGGTAGAAG
AT); for the change of codon 417A to T in V4, W9 (GAAG
ATAGGAATACAACTAACCAGAAGCCA); for the change
of codon 417/418AN to TK in V4, W14 (GATAGGAATAC
AACTAAACAGAAGCCAAAG); for the deletion of 420423KPKE in V4, W8 (AATACAGCTAACCAGCAGCATA
AAAGGAAT); and for the change of codon 477Q to K in V5,
W6 (TGGATTGATGGAAACAAAACTAATATCA). After
mutagenesis, a MroI-ClaI fragment containing the V4/V5
region was substituted for the corresponding fragment in
p239SpE3'. To create mutant 409D--N 422-425KEQH, which
has a variant 1-12 backbone, a 409D-to-N change, and a
KEQH insertion, overlap extension PCR using a mutagenic
internal primer was performed (13). The two separate amplifications in the first round of PCR were performed with primer
pairs W24-W26 and W23-W25, whose sequences are as follows: W24, GTAATTCCThITATGCTGTTCCTTTGGCTrC

TGTTAGTTGTATTCCTATCTTCTACCCAA'T'TTAGAA
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SIVmac251
SIVmac239

SIVmacl42
Variant 1-12
Variant 8-22

28
50
37
36

No. of nonidentical amino acids in gpl2O
SIVmac
SIVmac
Variant
Variant
239
142
1-12
8-22

28

50
45

45
20
20

37
20
52

52
53

17

36
20
53
17

ACCA; W23, ACTAAACAGAAGCCAAAGGAACAGCAT
AAAAGGAATITAC; W25, TCCCAATTCCAATCGATACA
GTTCTGCCAC, and W26, CCTGGAGGAGGAGATCCG
GAAGTrACCTlTC. The PCR-amplified DNA was purified by
Gene Clean (Bio 101 Inc., La Jolla, Calif.), and the second
round of PCR was performed with the outer set of oligonucleotide primers, W25-W26. After mutagenesis, a MroI-ClaI
fragment containing the V4/V5 region was substituted for the
corresponding fragment of variant 1-12. To create mutant
415/416NT-bSL, which has a SIVmac239 backbone and SL at
positions 415 and 416, overlap extension PCR (13) was again
used. The first round of PCR was performed with primers
W25-W27 and W26-W28. W27 has the sequence TGGGTA

GAAGATAGGAGTCTAGCTAACCAGAAGCCAAAG;
W28 has the sequence CTTT'GGCTTCTGGTTAGCTAGAC
TCCTATC'l'TCTACCCA. The PCR-amplified DNA was purified by Gene Clean (Bio 101), and the second round of PCR
was performed with W25-W26. After mutagenesis, a MroI-ClaI
fragment containing the V4/V5 region was substituted for the
corresponding fragment of SIVmac239. The mutated subclones that were selected for use were sequenced to verify the
desired mutations and the absence of any other changes in viral
sequences.
RIPA and precipitation with Sepharose-bound sCD4.
CEMx174 cells infected with virus were monitored microscopically for syncytium formation and were metabolically labeled
with [35S]methionine and [35S]cysteine around the peak of
syncytium formation. Cell-free supematant was harvested, and
the amount of p27 antigen was measured with a Coulter SIV
Core Ag Assay Kit (Coulter, Hialeah, Fla.). SIV corresponding
to the indicated amount of p27 antigen was lysed with radioimmunoprecipitation assay (RIPA) buffer (1% Triton, 2.5 mM
Tris, 150 mM NaCl, 1% deoxycholate, 0.1% sodium dodecyl
sulfate), and the radiolabeled gpl20 glycoproteins were reacted either with positive sera from SIVmac239-infected rhesus monkeys or with MAbs KK5, KK9, KK17, Senv7.1, and
SenvlO1.1 at 4°C in RIPA buffer. Protein A-Sepharose CL-4B
or protein A-Sepharose CL-4B previously bound to rabbit antimouse immunoglobulin G (Calbiochem, San Diego, Calif.) was
used to precipitate the gpl20-MAb complexes. For incubations
in which soluble CD4 (sCD4) binding was to be analyzed,
Nonidet P-40 (NP-40) buffer (0.1% NP-40 in 50 mM N-2hydroxyethylpiperazine-N'-2-ethanesulfonic acid [HEPES]250 mM NaCl) was used instead of RIPA buffer. sCD4
(provided by R. Sweet of SmithKline) was bound to activated
CH Sepharose 4B as instructed by the supplier (Pharmacia,
Piscataway, N.J.). Sepharose-bound sCD4 was used to precipitate complexes of gpl20 and antibody. The proteins were
electrophoresed through an 8% polyacrylamide gel, fluorographed, dried, and exposed to X-ray film.

5398

J. VIROL.

CHOI ET AL.

B

O/

A,

M.
X

S1V(+)~~
Senv 7.1

bW

i

Senv 107.1

bud

b4

KK5

id

KK9

bm

k

KK17

h4

h4

C

1-fA

t

wwwwwwwwww

SIV(+)

Senv 7.1

Senv 101.1

w

WMU

U

W

KK5

W

KK9

iMi

KKl7

i j

FIG. 2. Immunoprecipitation with MAbs Senv7.1, Senv1l1.1, KK5, KK9, and KK17. (A) Reactivity of gpl20 of cloned variants. (B) Reactivity
of gpl20 of recombinant derivatives of SIVmac239 and 1-12. SIV(+) indicates sera from a rhesus macaque infected with SIVmac239 as a positive
control. CEMx174 cells infected with the indicated cloned or recombinant virus were starved in methionine-cysteine-free RPMI for 1 h and then
labeled with [35S]methionine-cysteine for 16 h. 35S-labeled virus was harvested and disrupted with RIPA buffer (see Materials and Methods). SIV
equivalent to 100 ng of p278ag (measured by Coulter SIV Core Ag Assay) was used for each lane. Rabbit anti-mouse immunoglobulin G-bound
protein A-Sepharose beads were used to precipitate antibody-bound gpl20. Bands shown are gpl20. M indicates a mock infection, 239 indicates
a SIVmac239 infection, and 1-12 indicates infection with variant 1-12. 1-12 Vl 239 has a 1-12 backbone with the Vl region replaced by SIVmac239
Vl. 1-12 V4V5 239 has 1-12 backbone with the V4/V5 region replaced by SIVmac239 V4/V5. The nomenclature for the other recombinant viruses
follows the same pattern.

RESULTS

Reactivity of SIVmac envelope gpl2O. Five MAbs were used
for our experiments: Senv7.1, SenvlO1.1, KK5, KK9, and KK17
(8, 17, 18). These MAbs do not react with peptide or envelope
protein expressed in Escherichia coli, and they do not react
with denatured antigen in Western blots (immunoblots). Env
glycoprotein gpl20 of SIVmac251 does react well with these
MAbs by RIPA and by immunofluorescence tests with infected
cells. These properties, summarized in Table 1, indicate that
the five MAbs require native antigen for optimal reactivity.
These MAbs can neutralize the infectivity of SIVmac251, and
they have been classified in the same competition group (8, 11,
17, 18). Antibodies of this type are made by rhesus monkeys as
a natural response to SIV infection (24, 34).
The MAbs were tested for reactivity with a number of strains
of SIVmac derived from cloned DNA. SIVmac239 was previously derived by animal passage of SIVmac251 (9, 19, 30, 33).
SIVmacl42 was independently isolated from another rhesus
macaque of the same colony at the New England Regional
Primate Research Center (6, 9). The gpl2Os of the cloned
SIVmac251 and SIVmac239 used for our studies differ at only
28 of 525 residues in gpl20 (95% amino acid identity) (Fig. 1;
Table 2). The gp120 of SIVmacl42 is more distantly related,
with differences at 45 positions compared with gpl20 of
SIVmac239 (91% amino acid identity) and 50 positions compared with gpl20 of SIVmac251 (90% amino acid identity)
(Fig. 1; Table 2). Variants 1-12 and 8-22 were derived from
rhesus monkeys infected with cloned SIVmac239 (4, 5); these
variants differ at only 20 residues in gpl20 compared with
SIVmac239 (Fig. 1; Table 2).
The gpl2Os of all of these cloned viruses reacted equally well

by RIPA with sera from monkeys infected with SIVmac239 or
SIVmac251 (Fig. 2A). The five MAbs all recognized SIVmac239 gpl20, but they did not react or reacted poorly with
variants 1-12 and 8-22 (Fig. 2A). The gpl20 of SIVmacl42 was
recognized somewhat by KK17, but it did not react significantly
with the other four MAbs (Fig. 2A). The results obtained with
the five molecularly cloned viruses, summarized in Table 3,
indicate that the reactivities of the five neutralizing MAbs are
very sensitive to natural sequence variation in gpl20.
Variable domains responsible for loss of gpl20 recognition.
Eight recombinant clones were constructed by using SIVmac239 and variant 1-12 env sequences (Fig. 3). All recombinant clones were found to yield virus that was replication
competent in CEMx174 cells. Infected cells were labeled with
35S, and the virus produced from these cells was used for RIPA
analysis. The gp12Os of all recombinant viruses reacted equally

TABLE 3. Reactivities of MAbs with SIVmac gpl20 by RIPA
Virus

SIVmac251
SIVmac239
SIVmacl42
Variant 1-12
Variant 8-22

Reactivity'
KK5 KK9

Senv7.1

SenvlOl.1

+
+

+
+

+
+

+
+

-

-

-

-

KK17

SIV+b

+
+
+

+
+
+
+
+

-

a No or very weak reactivity, such as that present at some positions in Fig. 2,
is indicated by a minus sign.
b
RIPA results obtained with sera from an SIVmac239-infected rhesus monkey.
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FIG. 3. Composition of recombinant viruses and their reactivities in RIPA. Reactivity was determined from the data shown in Fig. 2 and other
repeated experiments which are not shown. The restriction enzyme sites used for recombinant constructions are indicated at the top. The presence
or absence of reactivity is indicated by + or -. Very weak reactivity, such as that seen in some positions in Fig. 3B, is indicated by -.

well with sera from SIV-infected monkeys (Fig. 2B). The
pattern of reactivity with recombinant viruses strongly indicated that loss of recognition by the MAbs was associated with
sequence changes in the V4/V5 region (Fig. 2B and 3).
Individual amino acid changes responsible for loss of recognition. On the basis of the natural sequence variation in the
V4 and V5 regions of the cloned viruses (Fig. 1), seven
site-specific mutations were created in SIVmac239. These
mutations were designed to test which specific sequences in
this region were responsible for loss of recognition by the five
MAbs (Table 4). All mutated clones yielded virus that was
replication competent in CEMx174 cells. Cells infected with
mutant virus were labeled with 35S, and labeled virus contained
in the supernatant was used for RIPA analysis. Sera from
SIV-infected monkeys reacted equally well with gpl20 of all
mutant viruses (Fig. 4; Table 4). A change of 409N to D,
deletion of KPKE at residues 420 to 423, and deletion of
KEQH at residues 422 to 425 each resulted in loss of recog-

nition by all five MAbs (Fig. 4; Table 4). All of these natural
sequence variations are in V4. However, changing 417A to T
or 417/418AN to TK (which created a potential N-linked
glycosylation site) did not alter, or altered only slightly, the
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TABLE 4. Reactivities of neutralizing MAbs with mutant
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" No or very weak reactivity, such as that seen at some positions in Fig. 4, is
indicated by a minus sign.
"
Each strain in parentheses indicates the clonal envelope within which the
indicated amino acids were mutated. 239, SIVmac239.
c RIPA results obtained with sera from a rhesus monkey infected with
SIVmac239.

FIG. 4. Immunoprecipitation of site-specific mutants with MAbs.
SIV(+) indicates sera from a rhesus macaque infected with SIVmac239 as a positive control. The indicated mutations were made in
the V4 or V5 domain of SIVmac239 gpl20. CEMx174 cells infected
with SIVmac239, variant 1-12, or site-specific mutant virus were
starved in methionine-cysteine-free RPMI for 1 h and then labeled
with [35S]methionine-cysteine for 16 h. 5S-labeled viruses were harvested and disrupted with RIPA buffer. SIV equivalent to 200 ng of
p27g"g (measured by Coulter SIV Core Ag Assay) was used for each
lane. Rabbit anti-mouse immunoglobulin G-bound protein A-Sepharose beads were used to precipitate MAbs-bound gpl2O. Bands shown
are

gpl20.
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recognition by the MAbs by RIPA (Fig. 4; Table 4). Changing
477Q to K in V5 did not significantly alter the recognition by
the five MAbs in RIPA (Fig. 4; Table 4).
To confirm and extend these findings, mutations were
constructed in the gpl20 of variant 1-12 in an attempt to
restore the reactivity. A single mutant virus was constructed in
which the 409 position was restored from N to D and the
KEQH sequence was reinserted at residues 422 to 425. The
remainder of the Env glycoprotein is exactly that of variant
1-12. These five changes in variant 1-12 were able to completely restore the reactivity to all five MAbs (Fig. 5).
CD4 and MAb binding sites. To examine the effect of sCD4
binding on recognition of SIVmac239 envelope glycoprotein by
the MAbs, 35S-labeled, NP-40-disrupted virus equivalent to
140 ng of p27 antigen was preincubated with sCD4 for 16 h.
Two different sCD4 concentrations, 2.5 and 20 ,ug/ml, were
used. Immunoprecipitation of gpl20 by MAbs KK5, KK9, and
KK17 was not decreased detectably by preincubation with
sCD4 under these conditions (Fig. 6A). Immunoprecipitation
by Senv7.1 and SenvlO1.1 was decreased by up to 35%
(measured by gel imaging densitometry) by the sCD4 preincubation.
35S-labeled virus equivalent to 140 ng of p24 antigen was
also preincubated with high concentrations of MAbs for 16 h at
4°C and used to analyze the effects on binding of sCD4.
Following preincubation, Sepharose-bound sCD4 was used to
precipitate gpl20. Binding of sCD4 to the SIVmac239 envelope was not affected by the MAb prebinding (Fig. 6B). This
result indicates that the binding domains of the MAbs and
sCD4 are not overlapping.
DISCUSSION

Sequence variations that accumulate in env with time of SIV
infection result from selective forces operating in vivo (5).
Sequence changes in env become fixed predominantly in
discrete variable domains, and within these variable domains, a

remarkably high percentage of nucleotide substitutions are
nonsynonymous (5, 16, 32). Thus, amino acid changes in the
discrete variable domains provide selective advantage to mutant virus. Neutralizing antibodies appear to be one of the
selective forces, since one result of the sequence variation is
escape from ongoing neutralizing antibody responses (4). However, it is not known to what extent other selective forces, such
as cell type and tissue tropism, may be influencing the fixation
of amino acid substitutions. Furthermore, it is not known
which variable domains are primarily responsible for the
escape from neutralization.
In this report, we have shown that natural sequence variation in SIV V4 can result in escape from neutralization by at
least one class of neutralizing antibodies. The neutralizing
antibodies that were used were raised against native env
antigen by immunization of mice with a vaccinia virus recombinant (8, 17, 18). Most of the neutralizing antibodies that were
identified from these studies, including the five used here,
required native antigen for optimal recognition (8, 17, 18).
These findings suggest that neutralizing antibodies to SIVmac251 that recognize discontinuous or conformational epitopes may predominate over those that recognize linear
epitopes, consistent with previous studies (15). The five MAbs
used in the present study are representative of a single, major,
cross-competition group (8, 11, 14, 18), and antibodies of this
type have been shown to appear in rhesus monkeys as a natural
response to SIV infection (24, 34). Sequences in V4 appear to
be uniformly important for recognition by this major class of
SIVmac neutralizing antibody.
Several neutralization epitopes in the envelope of SIVmac
have been previously reported. Some of the MAbs identified by
Kent et al. (18) and Benichou et al. (2) that neutralize SIVmac
infectivity react with peptides corresponding to amino acids
170 to 190 of gpl20. A weak type-specific neutralization
determinant was identified in a variable region of the transmembrane protein of SIVmac (20). Torres et al. (37), using
peptides to elicit antibodies, and Collignon et al. (8), using
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SenvlOl.1, KK5, KK9, and KK17, respectively, and then precipitated with sCD4-bound Sepharose beads. gpl20 bands are indicated. Sizes are
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peptide to block the neutralizing activity of polyclonal sera,
demonstrated that amino acids 410 to 430 in V4 of gpl20
contain a neutralization epitope. The 409 and 420-425 determinants described in the current report are within or near this
linear epitope described previously. Although extremely sensitive to sequence changes in V4, the five neutralizing antibodies used in this study do not react to any large extent with
synthetic peptides, with E. coli-produced subfragments, or with
denatured protein on Western blots, and thus they recognize
conformational or discontinuous epitopes.
How do these results on the important role of V4 for
recognition by one class of SIVmac neutralizing antibody relate
to sequence requirements for neutralization of HIV-1? Unfortunately, little work has been done on the effects of natural
sequence variation in HIV-1 V4 on recognition by conformation-sensitive MAbs that neutralize HIV (29). Berkower et al.
(3) have reported a major, conformation-dependent HIV-1
neutralization determinant mapping to a region of gpl20
(residues 342 to 511) that includes V4. It will be important to
learn whether natural sequence variation in V4 of HIV-1 may
similarly result in loss of recognition by some HIV-1 neutralizing antibodies.
The lack of reactivity of cloned SIVmacl42 and other
recombinants suggests that sequence changes outside of V4
may also result in escape from recognition by these five MAbs.
Comparison of the sequences in V4 of SIVmacl42 with V4
sequences of clones that do react (SIVmac251, SIVmac239,
and mutants 417A-4T, 417/418AN-4TK, and 415/416NT->SL)
would predict no sequence changes in V4 of SIVmacl42 that
should obviate recognition by the five MAbs (Fig. 2; Table 4).
Indeed, when the V4/V5 region of SIVmacl42 was substituted
in SIVmac239, positive reactivity was observed with all five
MAbs (7a). Similarly, exchange of Vl sequences did not alter
the pattern of recognition. SIVmacl42 contains three amino
acid changes at positions 327, 335, and 337 within the cysteine
loop corresponding to V3 of HIV-1 (Fig. 2), and these could
possibly be responsible for the loss of recognition. Kent et al.
(16a) have recently found that some SIVmac neutralization

escape mutants generated in vitro to this class of antibody
result from changes in V3, and Javaherian et al. (14) have
presented evidence for conformationally determined SIV neutralizing activity dependent upon appropriate interaction of
C-terminal sequences with V3.
The genetic approach that we have used is a powerful one
for studying neutralizing antibodies that recognize complex
conformational determinants. Because it utilizes the effects of
natural sequence variation, it allows dissection of the mechanisms involved in escape from immune surveillance. Continued
use of this approach should lead to a more detailed understanding of which variable domains are responsible for escape
from different classes of neutralizing antibodies.
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